FDA Approves KEYTRUDA as First-Line Combination Therapy, Irrespective of PD-L1 Expression

Posted by ALCF Staff on May 10th, 2017
No Comments

Congratulations, Merck, for the approval of KEYTRUDA® in first-line combo therapy irrespective of PD-1 expression. The improved responses seen with KEYTRUDA® plus pemetrexed/carboplatin regimen are significant, and highlight the importance of finding new approaches that address the unmet needs of patients with metastatic nonsquamous non-small cell lung cancer.

Read the full press release here

Comments are closed.